Scott Weiner to be panelist at PricewaterhouseCooper's "Shaking the Money Tree" event at the Embassy Suites Hotel in Cary, NC
MethylGene and Pharmion report preliminary clinical data at the 2007 AACR-NCI-EORTC International Conference
MethylGene Inc. (TSX:MYG) and Pharmion Corporation (NASDAQ:PHRM) today reported preliminary clinical data from the Companies' MGCD0103 Phase I/II combination trial with Gemzar® (Trial 006). The data were presented in a poster session at the 2007 AACR-NCI- EORTC International Conference on Molecular Targets and Cancer Therapeutics in San Francisco on October 24th, 2007.
Methylgene and Pharmion announce collaboration to develop sirtuin inhibitors as anti-cancer agents
MethylGene Inc. (TSX:MYG) and Pharmion Corporation (NASDAQ:PHRM) today announced a research collaboration for the development of novel small molecule inhibitors targeting sirtuins, a separate and distinct class of histone deacetylase enzymes (Class 3 HDACs) implicated in cell survival and death.
